Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response
The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use. Further complicating treatment, the diagnosis of MDD is not guided by objective criteria, resulting in the risk of under- or overtreatment. A number of markers of MDD and antidepressant response have been investigated at the genetic, epigenetic, gene expression and protein levels. Polymorphisms in genes involved in antidepressant metabolism (cytochrome P450 isoenzymes), antidepressant transport (ABCB1), glucocorticoid signalling (FKBP5) and serotonin neurotransmission (SLC6A4 and HTR2A) were among those included in the first pharmacogenetic assays that have been tested for clinical applicability. The results of these investigations were encouraging when examining patient-outcome improvement. Furthermore, a nine-serum biomarker panel (including BDNF, cortisol and soluble TNF-α receptor type II) showed good sensitivity and specificity in differentiating between MDD and healthy controls. These first diagnostic and response-predictive tests for MDD provided a source of optimism for future clinical applications. However, such findings should be considered very carefully because their benefit/cost ratio and clinical indications were not clearly demonstrated. Future tests may include combinations of different types of biomarkers and be specific for MDD subtypes or pathological dimensions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D. S., Quinn, K., Sanislow, C., & Wang, P. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09091379 · Cited by 7,067 · cited 3×
“The Research Domain Criteria (Insel et al. 2010) focus on constructs under the negative valence systems domain (i.”
BackgroundA Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · cited 2×
“However, one meta-analysis investigated the role of IL-1b serum level in major depression and reported no evidence of association (Dowlati et al. 2010).”
BackgroundInflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · cited 2×
“Conversely, both medically ill and medically healthy patients with MDD have been found to exhibit elevations in inflammatory cytokines and their soluble receptors in peripheral blood and CSF, as well as elevations in peripheral blood concentrations of acute phase proteins, chemokines, adhesion molecules and inflammato…”
BackgroundAssociations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
The State of US Health, 1990-2010: Burden of Diseases, Injuries, and Risk Factors
Murray, C. J. L. (2013) · JAMA · doi:10.1001/jama.2013.13805 · Cited by 2,438
Allelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221
Risch, N., Herrell, R., Lehner, T., Liang, K.-Y., Eaves, L., Hoh, J., Griem, A., Kovacs, M., Ott, J., & Merikangas, K. R. (2009) · JAMA · doi:10.1001/jama.2009.878 · Cited by 1,655 · cited 1×
“A number of genetic studies investigated the effect of the 5-HTTLPR polymorphism on susceptibility to MDD, and two meta-analyses reported absent or negligible effects (Munafo et al. 2009; Risch et al. 2009).”
BackgroundAllele-specific FKBP5 DNA demethylation mediates gene–childhood trauma interactions
Klengel, T., Mehta, D., Anacker, C., Rex-Haffner, M., Pruessner, J. C., Pariante, C. M., Pace, T. W. W., Mercer, K. B., Mayberg, H. S., Bradley, B., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3275 · Cited by 1,447 · cited 1×
“Demethylation of these CpGs leads to an enhanced induction of FKBP5 transcription by GR agonists and is associated with GR resistance (Klengel et al. 2013).”
BackgroundPlacebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 1×
“Placebo response is a major concern for drug trials, as well as for biomarker investigations, and likely has a significant genetic component (Walsh et al. 2002; Tiwari et al. 2013; Holmes et al. 2016).”
BackgroundBinder, E. B., Salyakina, D., Lichtner, P., Wochnik, G. M., Ising, M., Pütz, B., Papiol, S., Seaman, S., Lucae, S., Kohli, M. A., et al. (2004) · Nature Genetics · doi:10.1038/ng1479 · Cited by 977 · cited 1×
“…2007; Smits et al. 2007; Maron et al. 2009) and one meta-analysis (Kato and Serretti 2010) reported that the S allele may also be a risk factor for the development of SSRI-induced side effects in Caucasian populations, though not for sexual dysfunction (Bishop et al. 2009; Strohmaier et al. 2011).”
BackgroundCRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies.
Valkanova, V., Ebmeier, K. P., & Allan, C. L. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.004 · Cited by 972 · cited 3×
“Two meta-analyses have con-firmed that major depression is associated with increased CRP levels (Howren et al. 2009; Valkanova et al. 2013).”
BackgroundBrunoni, A. R., Lopes, M., & Fregni, F. (2008) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009309 · Cited by 972
Binder, E. B. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.05.021 · Cited by 968
Liu, Y., Ho, R. C.-M., & Mak, A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.003 · Cited by 948
Hannestad, J., DellaGioia, N., & Bloch, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.132 · Cited by 914
Malberg, J. E., & Duman, R. S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300234 · Cited by 815
McKinnon, M. C., Yucel, K., Nazarov, A., & MacQueen, G. M. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0905 · Cited by 742 · cited 1×
“Indeed, depressed patients have reduced hippocampal volume and neurogenesis that is influenced by the number of episodes and duration of the illness (McKinnon et al. 2009; Wainwright and Galea 2013).”
BackgroundCytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735 · cited 2×
“The majority of studies demonstrated a reduction in CRP serum level after SSRI treatment (Leo et al. 2006; O’Brien et al. 2006; Pizzi et al. 2009) and treatment with non-SSRI antidepressants (Lanquillon et al. 2000; Tuglu et al. 2003).”
BackgroundDuman, R. S., & Voleti, B. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.004 · Cited by 714
Molendijk, M. L., Spinhoven, P., Polak, M., Bus, B. A. A., Penninx, B. W. J. H., & Elzinga, B. M. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.105 · Cited by 702 · cited 1×
“…in antidepressant-free depressed patients relative to both healthy controls and antidepressant-treated depressed patients (Brunoni et al. 2008; Molendijk et al. 2014) and an increase in BDNF levels after antidepressant treatment that was associated with the degree of symptom improvement…”
ResultMann, J. J., Huang, Y.-Y., Underwood, M. D., Kassir, S. A., Oppenheim, S., Kelly, T. M., Dwork, A. J., & Arango, V. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.729 · Cited by 613 · cited 2×
“Several pharmacogenetic studies (Perlis et al. 2003; Murphy et al. 2004; Popp et al. 2006; Hu et al. 2007; Smits et al. 2007; Maron et al. 2009) and one meta-analysis (Kato and Serretti 2010) reported that the S allele may”
BackgroundBessa, J. M., Ferreira, D., Melo, I., Marques, F., Cerqueira, J. J., Palha, J. A., Almeida, O. F. X., & Sousa, N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.119 · Cited by 598 · cited 1×
“Antidepressant drugs can both prevent stress-induced decrease of hippocampal neurogenesis and reverse it (Malberg and Duman 2003; Bessa et al. 2009).”
BackgroundGene×environment interactions at the serotonin transporter locus
Munafò, M. R., Durrant, C., Lewis, G., & Flint, J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.06.009 · Cited by 576
Ford, D. E., & Erlinger, T. P. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.9.1010 · Cited by 544
Elevated C-Reactive Protein Levels, Psychological Distress, and Depression in 73 131 Individuals
Wium-Andersen, M. K., Ørsted, D. D., Nielsen, S. F., & Nordestgaard, B. G. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.102 · Cited by 489
Polyakova, M., Stuke, K., Schuemberg, K., Mueller, K., Schoenknecht, P., & Schroeter, M. L. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.11.044 · Cited by 488 · cited 2×
“more than in non-responders, but insufficient data are available for comparing plasma levels in responders versus non-responders (Polyakova et al. 2015).”
BackgroundMiR-16 Targets the Serotonin Transporter: A New Facet for Adaptive Responses to Antidepressants
Baudry, A., Mouillet-Richard, S., Schneider, B., Launay, J.-M., & Kellermann, O. (2010) · Science · doi:10.1126/science.1193692 · Cited by 480
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder
Kato, M., & Serretti, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.116 · Cited by 450 · cited 2×
“2009) and one meta-analysis (Kato and Serretti 2010) reported that the S allele may”
BackgroundSelf-citationCattaneo, A., Gennarelli, M., Uher, R., Breen, G., Farmer, A., Aitchison, K. J., Craig, I. W., Anacker, C., Zunsztain, P. A., McGuffin, P., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.191 · Cited by 436
Gratacòs, M., González, J. R., Mercader, J. M., de Cid, R., Urretavizcaya, M., & Estivill, X. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.025 · Cited by 428
Tuglu, C., Kara, S. H., Caliyurt, O., Vardar, E., & Abay, E. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1566-z · Cited by 391
Interleukin-1β: A New Regulator of the Kynurenine Pathway Affecting Human Hippocampal Neurogenesis
Zunszain, P. A., Anacker, C., Cattaneo, A., Choudhury, S., Musaelyan, K., Myint, A. M., Thuret, S., Price, J., & Pariante, C. M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.277 · Cited by 388 · cited 1×
“IL-1b was demonstrated to regulate the activity of key members of the kynurenine pathway with an effect on the availability of tryptophan and the production of toxic metabolites, explaining its modulaing effect on neurogenesis in human hippocampal pro-genitor cells (Zunszain et al. 2012).”
BackgroundIncreased BDNF Promoter Methylation in the Wernicke Area of Suicide Subjects
Keller, S., Sarchiapone, M., Zarrilli, F., Videtič, A., Ferraro, A., Carli, V., Sacchetti, S., Lembo, F., Angiolillo, A., Jovanovic, N., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.9 · Cited by 379 · cited 2×
“reported in Wernicke’s area (Keller et al. 2010) and per-”
BackgroundFuchikami, M., Morinobu, S., Segawa, M., Okamoto, Y., Yamawaki, S., Ozaki, N., Inoue, T., Kusumi, I., Koyama, T., Tsuchiyama, K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023881 · Cited by 378
Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity.
Cowansage, K., LeDoux, J., & Monfils, M.-H. (2010) · Current Molecular Pharmacology · doi:10.2174/1874467211003010012 · Cited by 372 · cited 2×
“BNDF is implicated in processes that modulate learning, memory and mood (Soule et al. 2006; Cowansage et al. 2010).”
BackgroundMeta-analysis of the placebo response in antidepressant trials.
Rief, W., Nestoriuc, Y., Weiss, S., Welzel, E., Barsky, A. J., & Hofmann, S. G. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.029 · Cited by 346 · cited 2×
“Furthermore, few studies include or adjust for placebo response, which has been shown to account for 67.6% of the efficacy observed in anti-depressant treatment (Rief et al. 2009).”
BackgroundInfluentialPorcelli, S., Fabbri, C., & Serretti, A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.10.003 · Cited by 331 · cited 1×
“Genetic tests for use in predicting antidepressant response include genes involved in antidepressant metabolism (the cytochrome P450 (CYP) superfamily; Porcelli et al. 2011), antidepressant transport (ABCB1) and antidepressant drug targets.”
BackgroundSelf-citationVogelzangs, N., Duivis, H. E., Beekman, A. T. F., Kluft, C., Neuteboom, J., Hoogendijk, W., Smit, J. H., de Jonge, P., & Penninx, B. W. J. H. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.8 · Cited by 323
Association of high-sensitivity C-reactive protein with de novo major depression
Pasco, J. A., Nicholson, G. C., Williams, L. J., Jacka, F. N., Henry, M. J., Kotowicz, M. A., Schneider, H. G., Leonard, B. E., & Berk, M. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.076430 · Cited by 321 · cited 2×
“for de novo depression in women (Pasco et al. 2010), depression in men (Ford and Erlinger, 2004; Liukkonen et al.”
BackgroundIssler, O., Haramati, S., Paul, E. D., Maeno, H., Navon, I., Zwang, R., Gil, S., Mayberg, H. S., Dunlop, B. W., Menke, A., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.042 · Cited by 318 · cited 2×
“Finally, miR-135a levels in blood and brain of depressed human patients were demonstrated to be lower compared to controls (Issler et al. 2014).”
BackgroundPoor replication of candidate genes for major depressive disorder using genome-wide association data
Bosker, F. J., Hartman, C. A., Nolte, I. M., Prins, B. P., Terpstra, P., Posthuma, D., van Veen, T., Willemsen, G., DeRijk, R. H., de Geus, E. J., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.38 · Cited by 309
Lopez, J. P., Lim, R., Cruceanu, C., Crapper, L., Fasano, C., Labonte, B., Maussion, G., Yang, J. P., Yerko, V., Vigneault, E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3582 · Cited by 308
Philibert, R. A., Sandhu, H., Hollenbeck, N., Gunter, T., Adams, W., & Madan, A. (2008) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30657 · Cited by 300 · cited 2×
“An early study found a trend of association between history of MDD and increased SLC6A4 methylation (Philibert et al. 2008), and a subsquent study reported that depressive symptoms were more common among adolescents with elevated SLC6A4 methylation who carried the 5-HTTLPR S allele (Olsson et al.…”
BackgroundHosang, G. M., Shiles, C., Tansey, K. E., McGuffin, P., & Uher, R. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-7 · Cited by 292 · cited 1×
“Conversely, the rs6265 Met allele was demonstrated to moderate the relationship between life stress and depression (Hosang et al. 2014; Gutierrez et al. 2015).”
BackgroundVermeer, H., Hendriks-Stegeman, B. I., van der Burg, B., van Buul-Offers, S. C., & Jansen, M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020354 · Cited by 285 · cited 1×
“Further supporting this notion are studies showing that increased expression of the FKBP5 gene confers elevated GR resistance (Binder, 2009) and that glucocorticoids induce FKBP5 expression (Vermeer et al. 2003).”
BackgroundLekman, M., Laje, G., Charney, D., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Lipsky, R., Wisniewski, S. R., Manji, H., McMahon, F. J., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.10.026 · Cited by 284 · cited 2×
“Some studies did not take into account FKBP5 environment interactions and three studies found that the rs1360780 T allele was associated with increased risk of depression (Lekman et al. 2008; Lavebratt et al. 2010; Szczepankiewicz et al. 2014), two studies found an effect of rs4713916 (Zobel et al.”
ResultThe distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain
Burnet, P. W. J., Eastwood, S. L., Lacey, K., & Harrison, P. J. (1995) · Brain Research · doi:10.1016/0006-8993(95)00104-x · Cited by 283
Duivis, H. E., Vogelzangs, N., Kupper, N., de Jonge, P., & Penninx, B. W. J. H. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.01.002 · Cited by 282
Cumulative Depression Episodes Predict Later C-Reactive Protein Levels: A Prospective Analysis
Copeland, W. E., Shanahan, L., Worthman, C., Angold, A., & Costello, E. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.023 · Cited by 265
Association of SLC6A4 methylation with early adversity, characteristics and outcomes in depression
Kang, H.-J., Kim, J.-M., Stewart, R., Kim, S.-Y., Bae, K.-Y., Kim, S.-W., Shin, I.-S., Shin, M.-G., & Yoon, J.-S. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.01.006 · Cited by 254 · cited 5×
“…levels is still scarcely investigated and available data suggested a possible higher methylation status in treated versus untreated patients (Carlberg et al. 2014), but an enhanced reduction in suicidal ideation after treatment in subjects with low methylation levels (Kang et al. 2013a).”
BackgroundResultInfluentialOn the outside, looking in: A review and evaluation of the comparability of blood and brain “‐omes”
Tylee, D. S., Kawaguchi, D. M., & Glatt, S. J. (2013) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32150 · Cited by 243
The Effect of Paroxetine on 5-HT2A Receptors in Depression: An [18F]Setoperone PET Imaging Study
Meyer, J. H., Kapur, S., Eisfeld, B., Brown, G. M., Houle, S., DaSilva, J., Wilson, A. A., Rafi-Tari, S., Mayberg, H. S., & Kennedy, S. H. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.78 · Cited by 231
Bull, S. J., Huezo-Diaz, P., Binder, E. B., Cubells, J. F., Ranjith, G., Maddock, C., Miyazaki, C., Alexander, N., Hotopf, M., Cleare, A. J., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.48 · Cited by 228
Meta-analysis of molecular imaging of serotonin transporters in major depression
Gryglewski, G., Lanzenberger, R., Kranz, G. S., & Cumming, P. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.82 · Cited by 227 · cited 2×
“A reduction of SERT sites in the brain (particularly in midbrain and amygdala) of depressed patients has been demonstrated both by functional imaging (Gryglewski et al. 2014; Yeh et al. 2014) and post-mortem brain studies (Mann et al.”
BackgroundMethodGenetic predictors of response to antidepressants in the GENDEP project
Uher, R., Huezo-Diaz, P., Perroud, N., Smith, R., Rietschel, M., Mors, O., Hauser, J., Maier, W., Kozel, D., Henigsberg, N., et al. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.12 · Cited by 226 · cited 2×
“Several other studies investigated rs7997012 with negative results (Illi et al. 2009; Kishi et al. 2009; Perlis et al. 2009; Uher et al. 2009; Horstmann et al. 2010), 10 C.”
ResultSelf-citationGene expression in major depressive disorder
Jansen, R., Penninx, B. W. J. H., Madar, V, Xia, K., Milaneschi, Y., Hottenga, J. J., Hammerschlag, A. R., Beekman, A., van der Wee, N., Smit, J. H., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.57 · Cited by 224
BDNF promoter methylation and suicidal behavior in depressive patients
Kang, H.-J., Kim, J.-M., Lee, J.-Y., Kim, S.-Y., Bae, K.-Y., Kim, S.-W., Shin, I.-S., Kim, H.-R., Shin, M.-G., & Yoon, J.-S. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.08.001 · Cited by 218 · cited 5×
“…levels is still scarcely investigated and available data suggested a possible higher methylation status in treated versus untreated patients (Carlberg et al. 2014), but an enhanced reduction in suicidal ideation after treatment in subjects with low methylation levels (Kang et al. 2013a).”
BackgroundResultInfluentialGuidotti, G., Calabrese, F., Anacker, C., Racagni, G., Pariante, C. M., & Riva, M. A. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.225 · Cited by 200 · cited 2×
“Rats exposed to chronic mild stress show increased expression of FKBP5 as well as enhanced cytoplasmic levels of GR, primarily in ventral hippocampus and PFC. Chronic treatment with the antidepresant duloxetine is able to normalise such alterations (Guidotti et al. 2013).”
BackgroundGuintivano, J., Brown, T., Newcomer, A., Jones, M., Cox, O., Maher, B. S., Eaton, W. W., Payne, J. L., Wilcox, H. C., & Kaminsky, Z. A. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14010008 · Cited by 193
Couch, Y., Anthony, D. C., Dolgov, O., Revischin, A., Festoff, B., Santos, A. I., Steinbusch, H. W., & Strekalova, T. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.12.017 · Cited by 187 · cited 1×
“Mice susceptible to stress-induced anhedonia show elevated expression of TNF-a and SERT in the prefrontal area (Couch et al. 2013) and SSRIs inhibit the secretion of TNF-a in human T lymphocytes (Taler et al. 2007).”
BackgroundDong, C., Wong, M.-L., & Licinio, J. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.92 · Cited by 182
Papakostas, G. I., Shelton, R. C., Kinrys, G., Henry, M. E., Bakow, B. R., Lipkin, S. H., Pi, B., Thurmond, L., & Bilello, J. A. (2013) · Molecular Psychiatry · doi:10.1038/mp.2011.166 · Cited by 180 · cited 3×
“The G allele of a functional promoter polymorphism in the serotonin 1A receptor gene (HTR1A rs6295 or C-1019G) has been associated with increased 5-HT1A expression in raphe nucleus neurons both in vitro (Lemonde et al. 2003) and in vivo using PET (Parsey et al. 2010).”
BackgroundFrodl, T., Carballedo, A., Hughes, M. M., Saleh, K., Fagan, A., Skokauskas, N., McLoughlin, D. M., Meaney, J., O'Keane, V, & Connor, T. J. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.14 · Cited by 176
Uddin, M., Koenen, K. C., Aiello, A. E., Wildman, D. E., de los Santos, R., & Galea, S. (2011) · Psychological Medicine · doi:10.1017/s0033291710001674 · Cited by 174
Booij, L., Szyf, M., Carballedo, A., Frey, E.-M., Morris, D., Dymov, S., Vaisheva, F., Ly, V., Fahey, C., Meaney, J., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119061 · Cited by 174 · cited 2×
“Higher SLC6A4 promoter methylation in subjects with a history of childhood adversities was demonstrated (Kang et al. 2013b; Booij et al. 2015) and associated with family history of depression and more severe depressive psychopathology (Kang et al. 2013b).”
BackgroundSelf-citationMood disorders: Regulation by metabotropic glutamate receptors
Pilc, A., Chaki, S., Nowak, G., & Witkin, J. M. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.09.021 · Cited by 163 · cited 2×
“Interestingly, the tar-gets of miR-1202 are genes involved in neurological processes associated with the pathogenesis of MDD, including the GRM4 gene that has been implicated in the regulation of anxiety-related behaviours (Pilc et al. 2008; Davis et al. 2012).”
BackgroundLiukkonen, T., Silvennoinen-Kassinen, S., Jokelainen, J., Räsänen, P., Leinonen, M., Meyer-Rochow, V. B., & Timonen, M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.016 · Cited by 163
Depression and C-Reactive Protein: Population-Based Health 2000 Study
Elovainio, M., Aalto, A.-M., Kivimäki, M., Pirkola, S., Sundvall, J., Lönnqvist, J., & Reunanen, A. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31819e333a · Cited by 157 · cited 2×
“2010), depression in men (Ford and Erlinger, 2004; Liukkonen et al. 2006; Elovainio et al. 2009; Vogelzangs et al. 2012), atypical depression (Hickman et al.”
BackgroundEpigenetic regulation of BDNF expression according to antidepressant response
Lopez, J. P., Mamdani, F., Labonte, B., Beaulieu, M.-M., Yang, J. P., Berlim, M. T., Ernst, C., & Turecki, G. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.38 · Cited by 146
Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?
Maes, M., Anderson, G., Kubera, M., & Berk, M. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.888417 · Cited by 140
BDNF promoter methylation and genetic variation in late-life depression
Januar, V, Ancelin, M.-L., Ritchie, K., Saffery, R., & Ryan, J. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.114 · Cited by 139 · cited 1×
“…of exon I was found as a possible diagnostic biomarker of MDD (Fuchikami et al. 2011), and higher methylation status of the BDNF promoter was associated with MDD (D’Addario et al. 2013; Carlberg et al. 2014; Dell’Osso et al. 2014; Januar et al. 2015) and post-stroke depression (Kim et al. 2013).”
BackgroundOlsson, C. A., Foley, D. L., Parkinson-Bates, M., Byrnes, G., McKenzie, M., Patton, G. C., Morley, R., Anney, R. J. L., Craig, J. M., & Saffery, R. (2010) · Biological Psychology · doi:10.1016/j.biopsycho.2009.12.003 · Cited by 137
Okada, S., Morinobu, S., Fuchikami, M., Segawa, M., Yokomaku, K., Kataoka, T., Okamoto, Y., Yamawaki, S., Inoue, T., Kusumi, I., et al. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.02.002 · Cited by 125 · cited 2×
“SLC6A4 methylation status was also investigated in relation to antidepressant treatment response, but with mixed results (Kang et al. 2013b; Domschke et al. 2014; Okada et al. 2014).”
BackgroundDell׳Osso, B., D׳Addario, C., Carlotta Palazzo, M., Benatti, B., Camuri, G., Galimberti, D., Fenoglio, C., Scarpini, E., Di Francesco, A., Maccarrone, M., et al. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.05.020 · Cited by 112
Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression
Iga, J.-I., Ueno, S.-I., Yamauchi, K., Numata, S., Kinouchi, S., Tayoshi-Shibuya, S., Song, H., & Ohmori, T. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.12.014 · Cited by 105 · cited 3×
“Another study focussed on mRNA levels in leukocytes demonstrated an opposite finding, i.e., higher CREB mRNA levels in MDD patients compared to controls (Iga et al. 2007).”
BackgroundResultFKBP5 polymorphism is associated with major depression but not with bipolar disorder
Szczepankiewicz, A., Leszczyńska-Rodziewicz, A., Pawlak, J., Narozna, B., Rajewska-Rager, A., Wilkosc, M., Zaremba, D., Maciukiewicz, M., & Twarowska-Hauser, J. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.04.002 · Cited by 100 · cited 6×
“Some studies did not take into account FKBP5 environment interactions and three studies found that the rs1360780 T allele was associated with increased risk of depression (Lekman et al. 2008; Lavebratt et al. 2010; Szczepankiewicz et al. 2014), two studies found an effect of rs4713916 (Zobel et al.”
ResultInfluentialSerotonergic gene expression and depression: implications for developing novel antidepressants
Lesch, K. P. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00351-7 · Cited by 93
Hickman, R. J., Khambaty, T., & Stewart, J. C. (2014) · Journal of Behavioral Medicine · doi:10.1007/s10865-013-9510-0 · Cited by 90
The epigenetic effects of antidepressant treatment on human prefrontal cortex BDNF expression
Chen, E. S., Ernst, C., & Turecki, G. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001422 · Cited by 88
Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications
Fabbri, C., & Serretti, A. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0594-9 · Cited by 84 · cited 2×
“Despite controversial pharmacogenetic findings being reported for the FKBP5 gene, results obtained in a large sample of Caucasian subjects suggested that rs1360780, rs3800373, rs4713916 and rs352428 poly-morphisms may modulate antidepressant response (Fabbri and Serretti, 2015).”
BackgroundResultSelf-citationAlmeida, O. P., Norman, P. E., Allcock, R., Bockxmeer, F. V., Hankey, G. J., Jamrozik, K., & Flicker, L. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyp199 · Cited by 80
Hohne, N., Poidinger, M., Merz, F., Pfister, H., Bruckl, T., Zimmermann, P., Uhr, M., Holsboer, F., & Ising, M. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu087 · Cited by 74 · cited 2×
“In healthy subjects the rs1360780 CC genotype showed an increase of FKBP5 mRNA levels after stress exposure compared to CT or TT genotypes, despite no genotype effect on mRNA expression found in remitted MDD patients (Hohne et al. 2015).”
BackgroundIgnácio, Z. M., Réus, G. Z., Abelaira, H. M., & Quevedo, J. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.06.036 · Cited by 65 · cited 2×
“CREB1 in the hippocampus and PFC of rats, and treatment with antidepressants also increased the levels of protein and mRNA of CREB1 and BDNF in the hippocampus of rats (Ignacio et al. 2014).”
BackgroundLorenzo-Luaces, L. (2015) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796015000542 · Cited by 55
Measures of anxiety, sensorimotor function, and memory in male and female mGluR4−/− mice
Davis, M. J., Haley, T., Duvoisin, R. M., & Raber, J. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.12.037 · Cited by 52 · cited 2×
“Interestingly, the tar-gets of miR-1202 are genes involved in neurological processes associated with the pathogenesis of MDD, including the GRM4 gene that has been implicated in the regulation of anxiety-related behaviours (Pilc et al. 2008; Davis et al. 2012).”
BackgroundCalati, R., Crisafulli, C., Balestri, M., Serretti, A., Spina, E., Calabrò, M., Sidoti, A., Albani, D., Massat, I., Höfer, P., et al. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.03.005 · Cited by 45 · cited 2×
“Findings for CREB1 and antidepressant response are also inconsistent (Murphy et al. 2004; Wilkie et al. 2007; Serretti et al. 2011; Calati et al. 2013) and negative findings have also been reported (Dong et al.”
ResultSelf-citation
Cited by
Prognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications
Li, Z., Ruan, M., Chen, J., & Fang, Y. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00638-3 · Cited by 326
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Becker, A. M., Holze, F., Grandinetti, T., Klaiber, A., Toedtli, V. E., Kolaczynska, K. E., Duthaler, U., Varghese, N., Eckert, A., Grünblatt, E., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2487 · Cited by 184
Kessler, R. C. (2018) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000377 · Cited by 103
Metadata
- Authors
- Fabbri, C., Hosak, L., Mössner, R., Giegling, I., Mandelli, L., Bellivier, F., Claes, S., Collier, D. A., Corrales, A., Delisi, L. E., Gallo, C., Gill, M., Kennedy, J. L., Leboyer, M., Lisoway, A., Maier, W., Marquez, M., Massat, I., Mors, O., Muglia, P., Nöthen, M. M., O’Donovan, M. C., Ospina-Duque, J., Propping, P., Shi, Y., St Clair, D., Thibaut, F., Cichon, S., Mendlewicz, J., Rujescu, D., & Serretti, A.
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2016-09-07
- Volume
- 18
- Issue
- 1
- Pages
- 5-28
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2512973285
- Cited by
- 81
- References
- 86
- FWCI
- 9.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.